Interferon-free strategies with a Nucleoside/nucleotide analogue

Seminars in Liver Disease

Volumn 34, Issue 1, 2014, Pages 37-46

  Feld, Jordan J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

direct acting antivirals; hepatitis C virus; interferon; nucleoside inhibitors; sofosbuvir

Indexed keywords

ALISPORIVIR; BALAPIRAVIR; DACLATASVIR; INTERFERON; LEDIPASVIR; MERICITABINE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; MIRAVIRSEN; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VALOPICITABINE; 2-((5-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; NUCLEOSIDE; NUCLEOTIDE; PROTEINASE INHIBITOR; URIDINE PHOSPHATE; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS GENOME; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG DESIGN; DRUG RESISTANCE, VIRAL; FLUORENES; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MOLECULAR TARGETED THERAPY; NUCLEOSIDES; NUCLEOTIDES; PROTEASE INHIBITORS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84899621215     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1371009     Document Type: Article

References (54)

1. Scheel T. K., Rice C. M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med: 2013; 19 7 837 849
2. Sarrazin C., Hézode C., Zeuzem S., Pawlotsky J. M. Antiviral strategies in hepatitis C virus infection. J Hepatol: 2012; 56 01 S88 S100
3. Rong L., Dahari H., Ribeiro R. M., Perelson A. S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med: 2010; 2 30 30ra32
4. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology: 2010; 138 2 447 462
5. Pawlotsky J. M. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology: 2011; 140 3 746 754
6. Feld J. J., Hoofnagle J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature: 2005; 436 7053 967 972 (Pubitemid 41191673)
7. Pawlotsky J. M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology: 2011; 53 5 1742 1751
8. Feld J. J. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals? Gastroenterology: 2012; 142 6 1356 1359
9. Feld J. J., Nanda S., Huang Y., et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology: 2007; 46 5 1548 1563 (Pubitemid 350155537)
10. Sarasin-Filipowicz M., Oakeley E. J., Duong F. H., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A: 2008; 105 19 7034 7039 (Pubitemid 351754525)
11. Migliaccio G., Tomassini J. E., Carroll S. S., et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem: 2003; 278 49 49164 49170
12. Le Pogam S., Jiang W. R., Leveque V., et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology: 2006; 351 2 349 359 (Pubitemid 44108072)
13. Pawlotsky J. M., Najera I., Jacobson I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther: 2012; 17 3 411 423
14. Le Pogam S., Seshaadri A., Ewing A., et al. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis: 2010; 202 10 1510 1519
15. Mariño Z., van Bömmel F., Forns X., Berg T. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut: 2014; 63 2 207 215
16. Summa V., Ludmerer S. W., McCauley J. A., et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother: 2012; 56 8 4161 4167
17. Kowdley K., et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT 267, ABT-333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. Hepatology: 2012; 56 S1
18. Janssen H. L., Reesink H. W., Lawitz E. J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med: 2013; 368 18 1685 1694
19. Garcia-Rivera J. A., Bobardt M., Chatterji U., et al. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob Agents Chemother: 2012; 56 10 5113 5121
20. Legrand-Abravanel F., Nicot F., Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin Investig Drugs: 2010; 19 8 963 975
21. Lewis W., Levine E. S., Griniuviene B., et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A: 1996; 93 8 3592 3597
22. Lewis W., Day B. J., Copeland W. C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov: 2003; 2 10 812 822 (Pubitemid 37361813)
23. Toniutto P., Fabris C., Bitetto D., Fornasiere E., Rapetti R., Pirisi M. Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs: 2007; 8 2 150 158 (Pubitemid 46438469)
24. Bristol-Myers Squibb. Bristol-Myers Squibb discontinues development of BMS-986094, an investigational NS5B nucleotide for the treatment of hepatitis C. Available at: http://bms.newshq.businesswire.com/press-release/financial-news/ bristol-myers-squibb-discontinues-development-bms-986094-investigationa2012. Accessed December 30, 2013
25. Pockros P. J. Lessons learned from failed clinical trials in hepatitis C drug development. Available at: http://www.ihlpress.com/pdf%20files/hepdart09- presentations/clinical-trial-design/6-MAC-Pockros-HEPDART09.pdf. Accessed February 10, 2014
26. Vertex. Vertex provides update on ongoing all-oral studies of VX-135 in hepatitis C. Available at: http://investors.vrtx.com/releasedetail.cfm? ReleaseID=7804562013. Accessed December 30, 2013
27. Jacobson I. M., Gordon S. C., Kowdley K. V., et al. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med: 2013; 368 20 1867 1877
28. Charlton M., et al. Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study. Hepatology: 2013; 58 S1
29. Sofia M. J., Bao D., Chang W., et al. Discovery of a β-d-2′- deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem: 2010; 53 19 7202 7218
30. Gane E. J., Stedman C. A., Hyland R. H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med: 2013; 368 1 34 44
31. Lalezari L., Nelson D., Hyland R., et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study. J Hepatol: 2013; 59 S1
32. Osinusi A., Meissner E. G., Lee Y. J., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA: 2013; 310 8 804 811
33. Sovaldi. Highlights of prescribing information. Available at: http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/sovaldi/ sovaldi-pi.pdf. Accessed December 30, 2013
34. Jacobson I., et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study. Hepatology: 2013; 58 S1
35. Palanisamy N., Danielsson A., Kokkula C., et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res: 2013; 99 1 12 17
36. Bae A., Sun S. C., Qi X., et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother: 2010; 54 12 5288 5297
37. Sulkowski M. S., GD, Rodriguez-Torres M., et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCG GT 1, 2, or 3. Hepatology: 2012; 56 S1
38. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013. Gastroenterol Hepatol (N Y). 2013; 9(6 Suppl 3): 1-18
39. Lawitz E., Poordad F. F., Pang P. S., et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet: 2013
40. Gilead. Gilead announces SVR12 rates from three phase 3 studies evaluating a once-daily fixed-dose combination of sofosbuvir and ledipasvir for Genotype 1 hepatitis c patients. Available at: http://www.gilead.com/news/press- releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies- evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for- genotype-1-hepatitis-c-patients?mode=print-sthash.B2jn6Vun.dpuf. Accessed December 30, 2013
41. Kohli A., et al. Combination oral, ribavirin free, antiviral therapy to optimize treatment outcomes for hepatitis C GT-1 treatment naive patients: interim results from the NIAID SYNERGY trial. Hepatology: 2013; 58 S1
42. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med: 2013; 368 20 1878 1887
43. Zeuzem S., et al. Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial. Hepatology: 2013; 58 S1
44. Lawitz E., et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology: 2013; 58 S1
45. Goossens N., Negro F. Is the genotype 3 of the hepatitis C virus the new villain? Hepatology: 2013
46. Elfiky A. A., Elshemey W. M., Gawad W. A., Desoky O. S. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J: 2013; 32 1 75 80
47. Ruane P. J., et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian ancestry. Hepatology: 2013; 58 S1 Abstract 1090
48. Tong X., Le Pogam S., Li L., et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis: 2013
49. Pawlotsky J. M., Dahari H., Neumann A. U., et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology: 2004; 126 3 703 714 (Pubitemid 38298318)
50. Wedemeyer H., Jensen D., Herring R. Jr., et al. PROPEL Investigators. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology: 2013; 58 2 524 537
51. Feld J. J., et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Hepatology: 2012; 56 (4, Suppl): 81A
52. Fry J., et al. VX-135, a once-daily nucleotide HCV polymerase inhibitor, was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment-naive patients with genotype 1 HCV. Hepatology: 2013; 58 S1 Abstract 1104
53. Standring D. N., et al. A Novel Uridine Nucleotide Prodrug, IDX20963, and Its Potential for Use in a Low-Dose Direct-Acting Antiviral Regimen for HCV. Hepatology: 2013; 58 S1
54. Idenix. Idenix Pharmaceuticals announces update on development program for its lead HCV nucleotide prodrug candidate, IDX20963. Available at: http://ir.idenix.com/releasedetail.cfm?ReleaseID=7728222013. Accessed December 30, 2013